文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒症患者入院前使用钙通道阻滞剂与预后改善相关:一项基于人群的倾向评分匹配队列研究

Preadmission Use of Calcium Channel Blocking Agents Is Associated With Improved Outcomes in Patients With Sepsis: A Population-Based Propensity Score-Matched Cohort Study.
PubMed 文献 · Crit Care Med · 2017-01-01
一句话结论台湾全民健康保险数据库中,脓毒症患者入院前使用钙通道阻滞剂与30天死亡率降低6%相关(HR 0.94),但为观察性关联。

该研究利用台湾全民健康保险研究数据库,识别住院严重脓毒症患者51,078例,其中19,742例入院前接受过钙通道阻滞剂治疗。采用多因素校正Cox比例风险模型和倾向评分分析,并以β受体阻滞剂作为活性对照以检验健康使用者偏倚。结果显示,钙通道阻滞剂使用与倾向评分校正后30天死亡率降低相关(HR 0.94;95%CI 0.89-0.99),获益可延伸至90天死亡率(HR 0.95;95%CI 0.89-1.00);而β受体阻滞剂使用与30天(HR 1.06;95%CI 0.97-1.15)或90天死亡率(HR 1.00;95%CI 0.90-1.11)改善无关。亚组分析提示钙通道阻滞剂对男性、40-79岁、低合并症负担及合并心血管疾病、糖尿病或肾脏疾病的患者可能更有利。

要点

  • 在51,078例住院严重脓毒症患者中,19,742例入院前使用钙通道阻滞剂,倾向评分校正后30天死亡率HR 0.94(95%CI 0.89-0.99)。
  • 钙通道阻滞剂的获益可延伸至90天死亡率(HR 0.95;95%CI 0.89-1.00),但置信区间上限达1.00。
  • 活性对照β受体阻滞剂与30天死亡率(HR 1.06;95%CI 0.97-1.15)或90天死亡率(HR 1.00;95%CI 0.90-1.11)改善无关。
  • 亚组分析提示钙通道阻滞剂对男性、40-79岁、低合并症负担及合并心血管疾病、糖尿病或肾脏疾病的患者可能更有利。
  • 作者结论认为,脓毒症发生前入院前钙通道阻滞剂治疗与死亡率降低6%相关。

适用人群与场景

  • 从台湾全民健康保险研究数据库通过国际疾病分类第九版临床修改编码识别的住院严重脓毒症患者。
  • 研究共识别51,078例脓毒症患者,其中19,742例在入院前接受过钙通道阻滞剂治疗。

研究设计与关键结果

  • 研究类型为基于人群的匹配队列研究,数据来源为台湾全民健康保险研究数据库,共纳入51,078例脓毒症患者,其中19,742例入院前接受钙通道阻滞剂治疗。
  • 倾向评分校正后,钙通道阻滞剂使用与30天死亡率降低相关(HR 0.94;95%CI 0.89-0.99),获益可延伸至90天死亡率(HR 0.95;95%CI 0.89-1.00)。
  • β受体阻滞剂使用与30天死亡率(HR 1.06;95%CI 0.97-1.15)或90天死亡率(HR 1.00;95%CI 0.90-1.11)改善无关。
  • 亚组分析显示,钙通道阻滞剂对男性、40-79岁、低合并症负担及合并心血管疾病、糖尿病或肾脏疾病的患者可能更有利。
  • 作者结论:在该全国性队列中,脓毒症发生前入院前钙通道阻滞剂治疗与死亡率降低6%相关。

证据类型、等级与局限

  • 证据类型:基于人群的倾向评分匹配队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,脓毒症发生前入院前钙通道阻滞剂治疗与死亡率降低6%相关;该关联来自观察性队列,原文未据此给出急诊或ICU的用药推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Use of calcium channel blockers has been found to improve sepsis outcomes in animal studies and one clinical study. This study determines whether the use of calcium channel blockers is associated with a decreased risk of mortality in patients with sepsis.

DESIGN: Population-based matched cohort study.

SETTING: National Health Insurance Research Database of Taiwan.

PATIENTS: Hospitalized severe sepsis patients identified from National Health Insurance Research Database by International Classification of Diseases, Ninth Revision, Clinical Modification codes.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: The association between calcium channel blocker use and sepsis outcome was determined by multivariate-adjusted Cox proportional hazard models and propensity score analysis. To examine the influence of healthy user bias, beta-blocker was used as an active comparator. Our study identified 51,078 patients with sepsis, of which, 19,742 received calcium channel blocker treatments prior to the admission. Use of calcium channel blocker was associated with a reduced 30-day mortality after propensity score adjustment (hazard ratio, 0.94; 95% CI, 0.89-0.99), and the beneficial effect could extend to 90-day mortality (hazard ratio, 0.95; 95% CI, 0.89-1.00). In contrast, use of beta-blocker was not associated with an improved 30-day (hazard ratio, 1.06; 95% CI, 0.97-1.15) or 90-day mortality (hazard ratio, 1.00; 95% CI, 0.90-1.11). On subgroup analysis, calcium channel blockers tend to be more beneficial to patients with male gender, between 40 and 79 years old, with a low comorbidity burden, and to patients with cardiovascular diseases, diabetes, or renal diseases.

CONCLUSIONS: In this national cohort study, preadmission calcium channel blocker therapy before sepsis development was associated with a 6% reduction in mortality when compared with patients who have never received calcium channel blockers.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Lee CC, Lee MG, Lee WC, et al. Preadmission Use of Calcium Channel Blocking Agents Is Associated With Improved Outcomes in Patients With Sepsis: A Population-Based Propensity Score-Matched Cohort Study. Crit Care Med. 2017. PMID: 28658023. doi:10.1097/CCM.0000000000002550

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。